CRESCENT BIOPHARMA, INC.(CBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,452 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CBIO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CRESCENT BIOPHARMA, INC. (CBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CBIO at 28.0/100 on a 32-signal composite quality model, placing it at rank #2,452 of 2,879 stocks — the bottom half of the AI-ranked universe. CBIO scores in the top quartile across institutional flow (88.4). Areas of concern include balance sheet strength (6.2) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CRESCENT BIOPHARMA, INC. reports quarterly revenue of $1.0M, net income of $-23.3M, free cash flow of $-9.1M. Top institutional holders of CBIO by reported 13-F value include FMR, BVF /IL, Fairmount Funds Management, based on the most recent SEC filings. CBIO trades on the Nasdaq exchange and files with the SEC under CIK 1253689. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRESCENT BIOPHARMA, INC. directly from SEC EDGAR. CRESCENT BIOPHARMA, INC.'s 13F Pro composite quality score has ranged between 27 and 28 since 2026, currently 28.0 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q1 2026
$1.0M
Net Income
Q1 2026
$-23.3M
Free Cash Flow
Q1 2026
$-9.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+14358.7% YoYNet Income
-229.7% YoYOperating Income
-222.0% YoYEPS (Diluted)
Total Assets
+363.8% YoYOp. Cash Flow
-54.0% YoY| Metric | FY 2025 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $10.8M +14358.7% | $75.0K -93.5% | $1.2M -88.6% | $10.2M | — | — |
| Net Income | $-153.9M -229.7% | $-46.7M +26.4% | $-63.4M -24.3% | $-51.0M +11.9% | $-57.9M -73.9% | $-33.3M |
| Operating Income | $-152.6M -222.0% | $-47.4M +25.3% | $-63.4M -23.2% | $-51.5M +16.1% | $-61.4M -80.9% | $-33.9M |
| EPS (Diluted) | — | $-0.45 +27.6% | $-0.61 -9.8% | $-0.56 +16.4% | $-0.67 | — |
| Total Assets | $240.3M +363.8% | $51.8M -45.1% | $94.3M -33.9% | $142.8M -15.0% | $168.0M +30.6% | $128.6M |
| Operating Cash Flow | $-71.5M -54.0% | $-46.5M +19.2% | $-57.5M -46.5% | $-39.2M +24.5% | $-52.0M -74.6% | $-29.8M |
Get alerted when CBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CRESCENT BIOPHARMA, INC. including:
Top Institutional Holders of CBIO
FMR LLC
$75.9M4,133,514 shBVF INC/IL
$50.5M2,748,763 shFairmount Funds Management LLC
$50.5M2,747,866 shVR Adviser, LLC
$39.2M2,133,576 shFCPM III SERVICES B.V.
$30.8M1,677,852 shBALYASNY ASSET MANAGEMENT L.P.
$27.7M1,510,033 shVestal Point Capital, LP
$27.6M1,500,000 shOpaleye Management Inc.
$24.1M1,312,615 shTANG CAPITAL MANAGEMENT LLC
$21.3M1,160,000 shVANGUARD CAPITAL MANAGEMENT LLC
$14.7M801,395 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $75.9M | 4,133,514 |
| BVF INC/IL | $50.5M | 2,748,763 |
| Fairmount Funds Management LLC | $50.5M | 2,747,866 |
| VR Adviser, LLC | $39.2M | 2,133,576 |
| FCPM III SERVICES B.V. | $30.8M | 1,677,852 |
| BALYASNY ASSET MANAGEMENT L.P. | $27.7M | 1,510,033 |
| Vestal Point Capital, LP | $27.6M | 1,500,000 |
| Opaleye Management Inc. | $24.1M | 1,312,615 |
| TANG CAPITAL MANAGEMENT LLC | $21.3M | 1,160,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.7M | 801,395 |
More Healthcare Companies
View all Healthcare →Put CBIO on your watchlist
Track score changes the day CRESCENT BIOPHARMA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CBIO a good stock to buy?
13F Pro's AI-powered analysis of CRESCENT BIOPHARMA, INC. (CBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CBIO are available on the CBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CRESCENT BIOPHARMA, INC.'s investment landscape.